14.69
-13.12 (-47.18%)
| Penutupan Terdahulu | 27.81 |
| Buka | 19.00 |
| Jumlah Dagangan | 8,829,301 |
| Purata Dagangan (3B) | 594,272 |
| Modal Pasaran | 793,826,880 |
| Harga / Jualan (P/S) | 536.52 |
| Harga / Buku (P/B) | 3.97 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Operasi (TTM) | -5,656.01% |
| EPS Cair (TTM) | -1.67 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -11.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.38% |
| Nisbah Semasa (MRQ) | 47.43 |
| Aliran Tunai Operasi (OCF TTM) | -82.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -70.18 M |
| Pulangan Atas Aset (ROA TTM) | -16.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -28.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Upstream Bio, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.00 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 14.84% |
| % Dimiliki oleh Institusi | 89.32% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2025 | 3,285,293 |
| Enavate Sciences Gp, Llc | 30 Sep 2025 | 2,459,703 |
| Omega Fund Management, Llc | 30 Sep 2025 | 1,356,293 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 51.00 (Mizuho, 247.18%) | Beli |
| Median | 43.00 (192.72%) | |
| Rendah | 40.00 (Evercore ISI Group, 172.29%) | Beli |
| Purata | 44.67 (204.08%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 26.81 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 18 Dec 2025 | 51.00 (247.17%) | Beli | 29.86 |
| LifeSci Capital | 02 Dec 2025 | 43.00 (192.72%) | Beli | 25.01 |
| Evercore ISI Group | 18 Nov 2025 | 40.00 (172.29%) | Beli | 25.56 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Jan 2026 | Pengumuman | Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 25 Nov 2025 | Pengumuman | Upstream Bio to Participate in Upcoming December Investor Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |